Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

Br J Pharmacol 100:651, 1990.
100. Kinoshita A, Urata H, Bumpus FM, Husain A:
Measurement of angiotensin I-converting enzyme
inhibition in the heart. Circ Res 73: 51, 1993.
101. Leonetti G, Cuspidi C: Choosing the right ACE inhibitor.
A guide to selection. Drugs 49:516, 1995.
102. Ruddy MC, Kostis JB, Frishman WH: Drugs that affect
the renin-angiotensin system. In: Frishman W,
Sonnenblick E, eds. Cardiovascular Pharmacotherapeutics.
New York: McGraw-Hill, 1998:131–192.
103. Briscoe TA, Dearing CJ: Clinical and economic
effects of replacing enalapril with benazepril in
hypertensive patients. Am J Health Syst Pharm
53:2191, 1996.
104. The SOLVD investigators. Effect of enalapril on
survival in patients with reduced left ventricular
ejection fractions and congestive heart failure. N
Engl J Med 325:293, 1991.
105. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The
effect of angiotensin-converting enzyme inhibition
on diabetic nephropathy. The Collaborative Study
Group. N Engl J Med 329:1456, 1993.
106. Sica DA: The HOPE Study: ACE inhibitors – are
their benefits a class effect or do individual agents
differ. Curr Opin Nephrol Hypertens 10:597, 2001.
107. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria
as a modifiable risk factor for the progression of
non-diabetic renal disease. Kidney Int 60:1131,
2001.
108. Wilson Tang WH, Vagelos RH, et al: Neurohormonal
and clinical responses to high- versus lowdose
enalapril therapy in chronic heart failure. J
Am Coll Cardiol 39:70, 2002.
109. Packer M, Poole-Wilson PA, Armstrong PW, et al:
Comparative effects of low and high doses of the
angiotensin-converting enzyme inhibitor, lisinopril,
on morbidity and mortality in chronic heart
failure. ATLAS Study Group. Circulation 100:2312,
1999.
110. Massie B: Neurohormonal blockade in chronic
heart failure. How much is enough. Can there be
too much J Am Coll Cardiol 39:79, 2002.
111. Tang WH, Vagelos RH, Yee YG, et al: Neurohormonal
and clinical responses to high- versus lowdose
enalapril therapy in chronic heart failure. J
Am Coll Cardiol 39:70, 2002.
112. Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al:
High- versus low-dose ACE inhibition in chronic
heart failure. A double-blind, placebo-controlled
study of imidapril. J Am Coll Cardiol 32:1811, 1998.
113. The American College of Cardiology/American
Heart Association Task Force on Practical Guidelines
(Committee on Evaluation and Management
of Heart Failure) Guidelines for the evaluation and
References to Chapter 9 9-5
management of heart failure. Circulation 92:2764,
1995.
114. Sica DA: Pharmacology and clinical efficacy of
angiotensin-receptor blockers. Am J Hypertens
14:242S, 2001.
115. Kassler-Taub K, Littlejohn T, Elliott W, et al: Comparative
efficacy of two angiotensin II receptor antagonists,
irbesartan and losartan, in mild to moderate
hypertension. Am J Hypertens 11:445, 1998.
116. Oparil S, Guthrie R, Lewin AJ, et al: An electivetitration
study of the comparative effectiveness of
two angiotensin II-receptor blockers, irbesartan
and losartan. Clin Ther 20:398, 1998.
117. Israili ZH: Clinical pharmacokinetics of angiotensin
II (AT1) receptor blockers in hypertension. J
Hum Hypertens 14 (Suppl 1): S73, 2000.
177a. Azilsartan medoxomil (Edarbi)—the eighth ARB.
The Medical Letter 43: 39, 2011.
118. Atacand (candesartan cilexetil). Product information.
Wilmington, DE: Astra Zeneca; 1998.
119. Riddell JG: Bioavailability of candesartan is unaffected
by food in healthy volunteers administered
candesartan cilexetil. J Hum Hypertens 11 (Suppl
2): S29, 1997.
120. Tenero D, Martin D, Ilson B, et al: Pharmacokinetics
of intravenously and orally administered eprosartan
in healthy males: Absolute bioavailability and effect of
food. Biopharm Drug Disp 19:351, 1998.
121. Cox PJ, Bush BD, Gorycki PD, et al: The metabolic
fate of eprosartan in healthy volunteers. Exp Toxicol
Pathol 48(Suppl II):75, 1996.
122. Bottorff MB, Tenero DM: Pharmacokinetics of
eprosartan in healthy subjects, patients with hypertension,
and special populations. Pharmacotherapy
19:73S, 1999.
123. Chapelsky MC, Martin DE, Tenero DM, et al: A
dose proportionality study if eprosartan in healthy
male volunteers. J Clin Pharmacol 38:34, 1998.
124. Vachharajani NN, Shyu WC, Chando TJ, et al: Oral
bioavailability and disposition characteristics of
irbesartan, an angiotensin antagonist, in healthy
volunteers. J Clin Pharmacol 38:702, 1998.
125. Vachharajani NN, Shyu WC, Mantha S, et al: Lack
of effect of food on the oral bioavailability of irbesartan
in healthy male volunteers. J Clin Pharmacol
38:433, 1998.
126. Lo MW, Goldberg MR, McCrea JB, et al: Pharmacokinetics
of losartan, an angiotensin II receptor
antagonist, and its active metabolite, EXP3174 in
humans. Clin Pharmacol Ther 58:641, 1995.
127. Cozaar (losartan). Product information. West
Point, PA: Merck & Co; 1995.
128. Laeis P, Puchler K, Kirch W: The pharmacokinetic
and metabolic profile of olmesartan medoxomil